Barclays Downgrades Biogen To Equal Weight On 'Mounting Uncertainties'

Barclays analyst Carter Gould downgraded Biogen to Equal Weight from Overweight with a price target of $280, down from $370.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.